Induction of apoptosis in mouse liver adenoma and carcinoma in vivo by transforming growth factor-beta1
Related Experiment Video
Updated: Sep 20, 2026

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System
Published on: July 30, 2018
Monika Chabicovsky1, Ute Wastl, Henryk Taper
1Institut für Krebsforschung der Universität Wien, Borschkegasse 8a, 1090, Wien, Austria.
Purpose:
In the liver, transforming growth factor beta-1 (TGF-beta1) constitutes a major negative growth regulating factor involved in the control of cell numbers; failure of this control mechanism has been associated with the development of liver cancer. Since no reports on the in vivo effects of exogenously administered TGF-beta1 on apoptosis in liver tumors have been published yet, we studied hepatocyte sensitivity to the proapoptotic action of TGF-beta1 in stages of chemically induced mouse liver carcinogenesis.
Methods:
Mouse liver carcinogenesis was initiated by a single dose of N-nitrosodiethylamine (NDEA, 90 mg/kg b.w., i.p.) to 5-week-old B6C3F1 mice. After 2 weeks, mice received either standard diet or a diet containing phenobarbital (PB, 90 mg/kg b.w) for 85 weeks. Four hours before being killed mice received a single dose of TGF-beta1 (56 microg or 200 microg TGF-beta1/kg of b.w., injected into the tail vein). Quantitative histological analysis of mitosis and apoptosis in normal liver tissue (NL), putative preneoplastic foci (PPF), hepatocellular adenoma (HCA), and hepatocellular carcinoma (HCC) was performed on H&E-stained liver sections.
Results:
In NDEA and NDEA + PB-treated mice, NL exhibited a very low incidence of apoptosis and mitosis, which increased in HCA and HCC. In the lesions apoptoses ranged between 0.03 and 0.6%. Two hundred micrograms of TGF-beta1/kg stimulated apoptoses in NL as well as in neoplastic lesions (significant increase in NL, HCA, and HCC); the most pronounced proapoptotic action of TGF-ss1 was observed in lesions of NDEA+PB pretreated mice (about 1.7%). Fifty-six microg TGF-beta1/kg had no detectable effect on apoptosis.
Conclusion:
These observations indicate that during chemically induced liver carcinogenesis in B6C3F1 mice basal rates of apoptoses in adenoma and carcinoma are higher than in normal liver and can be further increased by a proapoptotic cytokine.
Insights
Transforming growth factor beta-1 (TGF-beta1) increases apoptosis in liver tumors. This study shows TGF-beta1 can enhance the elimination of cancer cells in chemically induced liver carcinogenesis models.
Area of Science:
- Hepatology
- Cancer Biology
- Molecular Signaling
Background:
- Transforming growth factor beta-1 (TGF-beta1) is a key regulator of liver cell proliferation and apoptosis.
- Dysregulation of TGF-beta1 signaling is implicated in liver cancer development.
- The in vivo effects of exogenous TGF-beta1 on liver tumor apoptosis remain largely uncharacterized.
Purpose of the Study:
- To investigate the sensitivity of hepatocytes to the pro-apoptotic effects of TGF-beta1 during chemically induced liver carcinogenesis.
- To evaluate the impact of TGF-beta1 administration on apoptosis rates in normal liver and preneoplastic/neoplastic lesions.
Main Methods:
- Liver carcinogenesis was induced in B6C3F1 mice using N-nitrosodiethylamine (NDEA) with or without phenobarbital (PB) treatment.
- Mice received intravenous injections of TGF-beta1 (56 or 200 microg/kg) before tissue collection.
- Quantitative histological analysis assessed mitosis and apoptosis in normal liver, putative preneoplastic foci, hepatocellular adenoma, and hepatocellular carcinoma.
Main Results:
- Apoptosis and mitosis rates were low in normal liver but increased in hepatocellular adenoma (HCA) and hepatocellular carcinoma (HCC).
- A high dose of TGF-beta1 (200 microg/kg) significantly increased apoptosis in normal liver, HCA, and HCC.
- The pro-apoptotic effect of TGF-beta1 was most pronounced in lesions from mice treated with NDEA and PB.
Conclusions:
- Basal apoptosis rates are elevated in liver adenoma and carcinoma compared to normal liver during chemically induced carcinogenesis.
- Exogenous administration of TGF-beta1 can further enhance apoptosis in liver tumors.
- TGF-beta1 represents a potential therapeutic cytokine for increasing cancer cell death in liver cancer.
